Unexpected Hormone-Receptor-Positive Left Breast Cancer Found at Bilateral Mastectomy

Patient Info: Anonymized, female, 50s

Biomarkers: ER positive, PR positive, HER2 negative

The incidental left-breast cancer was removed during mastectomy, and hormonal therapy with left-axillary imaging follow-up was planned.

PubMed CentralRead more →

Breast Cancer: Stephanie's Survivor Story

Patient Info: Stephanie Spiesz, Female, 50s

As of June 2016, Stephanie was fully recovered and cancer-free after breast cancer diagnosed in November 2013 and treated with double mastectomy, chemotherapy and radiation.

Cleveland ClinicRead more →

Breast Cancer: Mauriel's Survivor Story

Patient Info: Mauriel Davis, Female

Biomarkers: Triple-positive; estrogen receptor-positive

As of May 2016, Mauriel had completed chemotherapy and surgery, had a positive 6-month follow-up, was moving beyond monthly visits, and felt she was recovering well; no explicit cancer-free/NED status was stated.

Cleveland ClinicRead more →

Stage I Breast Cancer: Shirley's Survivor Story

Patient Info: Shirley | Stage I

Shirley says she completed treatment and is now in remission after Stage I breast cancer.

Our Cancer StoriesRead more →

Stage II Invasive Ductal Carcinoma: Sarah's Patient Story

Patient Info: Sarah Cawley, Female, Under 40 | Stage II

As of August 2015, Sarah was still receiving treatment for Stage II invasive ductal carcinoma after modified radical mastectomy, 6 chemotherapy cycles, 25 radiation treatments and clinical trial participation.

Cleveland ClinicRead more →

Stage II BRCA1 Breast Cancer: Mariana's Patient Story

Patient Info: Mariana Torrado, female, Under 40 | Stage II

Biomarkers: BRCA1 positive

After breast cancer treatment and reconstruction, the patient described herself as a breast cancer survivor and was returning to normal activities.

MD AndersonRead more →

Invasive Lobular Carcinoma: Gretchen's Survivor Story

Patient Info: Gretchen Borzi, Female

Biomarkers: germline CDH1 mutation

The invasive focus measured less than 0.75 mm and had been removed during biopsy; surgery found no nodal spread.

Pediatric triple-negative breast carcinoma: modified radical mastectomy and tumor-free follow-up

Patient Info: Anonymized, Female, Under 40

Biomarkers: ER-negative; PR-negative; HER2-negative

As of April 2014, she was tumor-free after modified radical mastectomy and axillary clearance for pediatric triple-negative breast carcinoma.

PubMed CentralRead more →

Synchronous Stage IA breast cancer and Stage IIA lung adenocarcinoma: disease-free after surgery and adjuvant therapy

Patient Info: Anonymized, Female, 60s | Stage I

Biomarkers: Breast tumor: ER/PR positive, HER2 negative. Lung tumor: KRAS/EGFR wild type, ALK rearrangement not detected.

As of April 2014, more than 2 years of follow-up showed no recurrent disease after treatment of synchronous Stage IA breast cancer and Stage IIA lung adenocarcinoma.

PubMed CentralRead more →

Mixed epithelial and mesenchymal metaplastic breast carcinoma: no recurrence 1 year after surgery and adjuvant therapy

Patient Info: Anonymized, Female, 40s

Biomarkers: Mixed metaplastic breast cancer: epithelial part ER/PR/HER2-positive; mesenchymal part ER/PR-negative with weak HER2. Ki-67 ~20%.

As of March 2014, she was doing well with no recurrence or metastasis 1 year after modified radical mastectomy, adjuvant CEF/Taxotere chemotherapy, and tamoxifen.

PubMed CentralRead more →

Breast invasive ductal carcinoma with coexisting inflammatory myofibroblastic tumor: disease-free after mastectomy, TAC, and tamoxifen

Patient Info: Anonymized, Female, Under 40

Biomarkers: Breast cancer: ER/PR-positive with HER2 2+ and p53-positive. Separate inflammatory myofibroblastic tumor had ALK/vimentin/actin/S-100 markers.

As of August 2013, she remained disease-free 2 years after modified radical mastectomy, 6 courses of TAC chemotherapy, and tamoxifen.

PubMed CentralRead more →

Localized hormone receptor-positive breast cancer disease-free 5 years after endocrine therapy switch

Patient Info: Anonymized, Female, 40s

Biomarkers: ER-positive; PR-positive; HER2-negative; low Ki-67; Oncotype DX 12

After lumpectomy and 36 months of adjuvant hormonal treatment, she remained disease-free at her last examination in March 2013, 5 years after diagnosis.

PubMed CentralRead more →

ER/PR-positive mucinous breast cancer treated with mastectomy and tamoxifen

Patient Info: Anonymized, Female, Under 40

Biomarkers: ER-positive; PR-positive; HER2/neu not overexpressed; no pathogenic BRCA1 or BRCA2 mutations identified; chromosome 13q34 duplication

After radical right mastectomy with nipple and areola preservation followed by tamoxifen, she showed no evidence of local recurrence or metastasis of breast cancer.

PubMed CentralRead more →

Stage IV ER/PR-positive mucinous breast cancer: long-term no evidence of disease after surgery, AFTV, radiation, CEF, and endocrine therapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER-positive; PR-positive; delayed-type hypersensitivity to AFTV became pseudo-positive after vaccination and remained pseudo-positive 5.4 years later

Metastatic Site: Th7 vertebra

More than 6 years after primary surgery, she remained well with no evidence of vertebral metastasis activity, new metastasis, or local recurrence.

PubMed CentralRead more →

ER-positive breast cancer recurrence with renal metastasis inside angiomyolipoma

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: ER-positive; mammaglobulin-positive; e-cadherin-positive; GCDFP-15-positive; melan A positive in angiomyolipoma component

Metastatic Site: right subpectoral lymph node, left kidney

At 7 months after nephrectomy, she continued anti-estrogen hormonal therapy with no demonstrable progression of disease; surgical excision of the subpectoral lymph node was offered but declined.

PubMed CentralRead more →

BRCA1-associated right invasive ductal carcinoma followed by left acinic cell carcinoma of the breast

Patient Info: Anonymized, Female, 40s

Biomarkers: Constitutional BRCA1 mutation. Right breast cancer was ER/PR positive, HER2 negative; later left tumor was triple-negative with TP53 change.

After treatment for right invasive ductal carcinoma and later contralateral acinic cell carcinoma, she was alive and well 19 months after the acinic cell carcinoma surgery, with no evidence of disease while continuing hormonal therapy.

PubMed CentralRead more →

ER/PR-positive breast cancer with bilateral ovarian metastases controlled after oophorectomy and aromatase inhibitor

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative; CK7-positive; gross cystic disease fluid protein-15-positive; CK20-negative

Metastatic Site: bilateral ovaries

After bilateral oophorectomies and aromatase inhibitor therapy, pleural effusion resolved, CEA and CA 15-3 decreased below the normal upper limit, and she remained well with no further recurrence for 40 months.

PubMed CentralRead more →

Metastatic lobular breast cancer to gynecologic sites: disease-free after surgery and chemotherapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER-positive; PR-negative; HER2/C-Erb-B2-negative

Metastatic Site: vagina, uterus, ovaries

After treatment of vaginal, uterine, and ovarian metastases from lobular breast cancer, she was free from disease 12 months after completion surgery.

PubMed CentralRead more →

Hormone-positive breast cancer with axillary recurrence responding to hyperthermia, radiation, and chemotherapy

Patient Info: Anonymized, Female, 60s

Biomarkers: ER-positive; PR-positive; HER2-negative

The left axillary recurrence enlarged during weekly paclitaxel and radiotherapy, then became nearly flat and was assessed as a complete response 8 weeks after adding hyperthermia.

PubMed CentralRead more →

Metastatic lobular breast cancer to bladder trigone: partial response to tamoxifen

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: progesterone receptor-positive; genetic testing including BRCA1 negative

Metastatic Site: bladder trigone

As of January 2012, urge incontinence had resolved and PET showed decreased activity in the breast and bladder trigone lesions nearly 10 months after starting tamoxifen, consistent with clinical and partial radiologic remission.

PubMed CentralRead more →

Male DCIS breast cancer treated with mastectomy and negative sentinel node

Patient Info: Anonymized, Male, 60s | Stage 0

Biomarkers: ER-positive; PR-positive

Completed surgical treatment for Stage 0 DCIS with negative sentinel lymph node biopsy and clear margins; no additional cancer-directed therapy was described.

PubMed CentralRead more →

Stage III Triple-Negative Breast Cancer: Bridgette's Survivor Story

Patient Info: Bridgette, Female, 60s | Stage III

Biomarkers: Triple-negative breast cancer

Bridgette completed treatment and described herself as being in remission and free of cancer. Fear of recurrence continued to affect her survivorship.

Our Cancer StoriesRead more →

Recurrent HER2-amplified breast cancer: complete remission on trastuzumab-based therapy

Patient Info: Anonymized, Female, 40s | Stage Metastatic/Advanced

Biomarkers: Primary tumor was ER/PR negative and HER2 not amplified. Recurrent lymph-node disease became ER/PR positive and HER2 amplified by FISH.

Metastatic Site: left axillary and infraclavicular lymph nodes

After HER2-amplified nodal recurrence, paclitaxel plus trastuzumab produced complete clinical remission; she continued trastuzumab monotherapy with tolerable neuropathy.

PubMed CentralRead more →

Right breast ductal carcinoma with unusual sentinel-node drainage treated with lumpectomy and adjuvant therapy

Patient Info: Anonymized, Female, 40s

After lumpectomy, negative sentinel lymph node evaluation across 3 drainage territories, chemotherapy, radiotherapy, and hormone therapy, she remained free of disease 2 years and 6 months after surgery.

PubMed CentralRead more →